Tag: GlobeNewswire

Fifth annual Horizons of Identity Security report reveals a 40x gap between AI adoption and identity security readiness

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — Today from its annual Navigate conference, SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, released its fifth annual Horizons of Identity Security report, revealing that enterprise AI adoption has dramatically outpaced the identity security controls needed to govern it. The study finds that while 79% of organizations are now running AI agents in production, a mere 2% are using identity security tools specifically designed to manage and govern them — a 40-to-1 gap that exposes businesses to significant risk.

This gap is driven by a stark divergence in security maturity between human and non-human identities. While organizations have made impressive strides with human security—nearly halving those at Horizon 1 maturity from 45% in 2022 to just 23% today—the explosion of autonomous AI agents has introduced a new deficit. Agent identity starts from a steep lag, with 54% of organizations currently sitting at Horizon 1. With AI agents already active in production, enterprises do not have the luxury of a five-year runway to catch up; they must compress a five-year human security curve into a one-year agent timeline.

Wendy Wu, Chief Marketing Officer at SailPoint, said:
“Compressing a five-year maturity curve into a single year presents a massive operational challenge, starting with a fundamental awareness gap. Many organizations don’t yet realize that they do not have the right tools purpose-built for the scale and velocity of agent and non-human identity security. You cannot bridge this gap by asking human-speed tools to work faster; security must be built for machine speed from the ground up, with discovery, ownership, and access decisions happening in real time rather than on a quarterly review cycle. Enterprises waiting for their agent programs to mature the way their human programs did are going to find out the hard way that they don’t have five years.”

Key findings:

• AI adoption has severely outpaced security controls: AI agents now represent 22% of all non-human accounts, yet 85% of organizations continue to rely on legacy identity tools not designed for agentic identities.
• Overall maturity remains anchored at foundational levels. Roughly sixty percent of organizations remain in Horizons 1 and 2, while less than 1% have achieved Horizon 5. This lag is overwhelmingly driven by non-human identity deficits: 87% rate their human IAM capabilities as capable or better, while only 43% report mature processes for agentic access.
• A pronounced awareness gap masks operational vulnerability: 80% of leaders believe the gap in their current tooling is moderate or smaller, yet the operational reality is that only 15% can provision non-human access in real time. Similarly, 57% express confidence in meeting regulatory requirements, while only 43% feel prepared to produce verifiable evidence in an AI-related audit.
• Foundations remain the primary operational roadblock. Before enterprises can realize dynamic, intent-based security, they must first master baseline hygiene and visibility. Credential lifecycle management, shadow AI discovery, and real-time monitoring are rated as severe operational hurdles across the market.
• The business value of non-human identity security is immediate and measurable: Mature identity programs deliver significant business velocity. 62% of organizations that have invested in securing non-human identities report measurable productivity gains, and 46% report safer, faster AI deployment. Looking ahead, 76% of leaders expect stronger identity governance to improve their eligibility for — or the terms of — cyber insurance.

The report concludes that the mandate for security leaders is to move from a fragmented, human-centric approach to a unified identity fabric that governs all identity types—human, machine, and AI agent—with continuous, context-aware automation. By advancing from foundational tiers (Horizons 1-2)—where organizations struggle with manual controls and lack basic visibility—to advanced maturity (Horizons 4-5), enterprises gain the real-time visibility and automated policy enforcement needed to secure autonomous agents. This transition pays off well beyond basic compliance; mature organizations are twice as likely to realize significant productivity gains and three times more successful at deploying AI safely, effectively transforming compliance from a reactive audit scramble into a state of automated, continuous assurance. This is the only path to closing the security gap while enabling the full velocity of the autonomous enterprise.

About the report
The 2026 Horizons of Identity Security report is based on a global survey of 340 senior identity, IT, cybersecurity, and risk leaders conducted by SailPoint, evaluating organizations across strategy, operating models, talent, technical confidence, and technical capabilities against a five-tier maturity model ranging from Horizon 1 (No formal program) to Horizon 5 (Ecosystem integrated).

To read the full 2026-2027 “Horizons of Identity Security” report, please visit here.
Check out the livestream of SailPoint CMO Wendy Wu revealing the findings of this year’s Horizons report from SailPoint Navigate.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world’s leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275
shannon.paulk@sailpoint.com

NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review (BICR). Clinical benefit was observed with secondary endpoints such as PFS by investigator’s assessment and confirmed objective response rate by BICR. Although not yet mature, a trend toward an improvement in overall survival was also observed.  The safety profile observed in FURVENT was consistent with previous clinical studies of firmonertinib, with no new safety signals identified.

“These disappointing results are not what we hoped for, particularly for the patients with EGFR exon 20 insertion-mutant NSCLC who urgently need more effective treatment options,” said Bing Yao, Ph.D., Chairman, Chief Executive Officer of ArriVent. “While the safety profile observed with firmonertinib was consistent with previous clinical studies, FURVENT did not show a meaningful improvement in PFS over chemotherapy by BICR in this study. We are deeply grateful to the patients, investigators and clinical teams who made this program possible and are evaluating the full FURVENT dataset as we determine the most appropriate development path for firmonertinib.”

Key Results from the Phase 3 FURVENT Trial

The FURVENT key results are summarized below.

	Firmonertinib 240mg Median PFS (months)	Firmonertinib 160mg Median PFS (months)	Control  Median PFS (months)	p-value (240mg vs. control)	HR (95% CI) 240mg vs Control	HR (95% CI) 160mg vs Control	Confirmed ORR 240mg		Confirmed ORR 160mg		Confirmed ORR control
BICR	11.0 months	8.4 months	9.5 months	0.0654	0.75 (0.55, 1.02)	0.91 (0.67, 1.25)	60%		35%		33 %
Investigator’s Assessment	11.1 months	8.3 months	7.1 months		0.61 (0.46, 0.81)	0.86 (0.65, 1.14)	61%		41%		28%

The safety profile observed in FURVENT was consistent with previous clinical studies of firmonertinib, with no new safety signals identified. Treatment-emergent adverse events (TEAE) Grade ≥ 3 were 52% with firmonertinib 240mg, 53% with firmonertinib 160mg, and 55% with the control arm. Treatment-related adverse events (TRAE) Grade ≥ 3 were 26% with firmonertinib 240mg, 22% with firmonertinib 160mg, and 40% with the control arm.

About FURVENT
FURVENT (NCT05607550) is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being conducted jointly with our partner Allist. The FURVENT clinical trial is designed to assess the safety and efficacy of firmonertinib administered at either 160 mg or 240 mg, once-daily with each dose being compared to platinum-based chemotherapy with pemetrexed, the current first-line standard of care. The primary endpoint of this study is PFS by BICR per RECIST 1.1. Secondary endpoints include overall survival (OS), PFS by investigator’s assessment, confirmed objective response rate by BICR, and in patients with brain metastases at baseline, brain-specific CNS overall response rate (CNS-ORR) and CNS-PFS by modified RECIST (mRECIST). The study enrolled 398 patients globally, including from sites in the United States, Europe and certain Asian countries including Japan and China.

About Firmonertinib
Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is approved in China for first-line advanced non-small-cell lung cancer (NSCLC) patients with EGFR exon 19 deletion or L858R mutations, with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, both known as EGFR classical mutations, as well as for with exon 20 insertion mutations who have experienced disease progression during or after platinum-containing chemotherapy, or who are intolerant to platinum-containing chemotherapy.

Firmonertinib was granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. Firmonertinib was also granted U.S. FDA Orphan Drug Designation for the treatment of NSCLC with EGFR mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations.

Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 3 study in first line NSCLC patients with EGFR PACC mutations (ALPACCA; NCT07185997).

About EGFR mutant NSCLC
Globally, lung cancer is the leading cause of cancer-related deaths among men and women. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases. Mutational activation of the EGFR is a frequent and early event in the development of NSCLC. EGFR mutations are divided into classical and uncommon. EGFR exon 20 insertion mutations are a group of uncommon EGFR mutations and constitute approximately 9% of all EGFR mutations. PACC mutations are another group of uncommon EGFR mutations and represent approximately 12% of all EGFR mutations. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need.

About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our business strategy, our plans, our evaluation of the full FURVENT dataset, and our determination of the appropriate development path for firmonertinib, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 5, 2026 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Fifth annual Horizons of Identity Security report reveals a 40x gap between AI adoption and identity security readiness

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — Today from its annual Navigate conference, SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, released its fifth annual Horizons of Identity Security report, revealing that enterprise AI adoption has dramatically outpaced the identity security controls needed to govern it. The study finds that while 79% of organizations are now running AI agents in production, a mere 2% are using identity security tools specifically designed to manage and govern them — a 40-to-1 gap that exposes businesses to significant risk.

This gap is driven by a stark divergence in security maturity between human and non-human identities. While organizations have made impressive strides with human security—nearly halving those at Horizon 1 maturity from 45% in 2022 to just 23% today—the explosion of autonomous AI agents has introduced a new deficit. Agent identity starts from a steep lag, with 54% of organizations currently sitting at Horizon 1. With AI agents already active in production, enterprises do not have the luxury of a five-year runway to catch up; they must compress a five-year human security curve into a one-year agent timeline.

Wendy Wu, Chief Marketing Officer at SailPoint, said:
“Compressing a five-year maturity curve into a single year presents a massive operational challenge, starting with a fundamental awareness gap. Many organizations don’t yet realize that they do not have the right tools purpose-built for the scale and velocity of agent and non-human identity security. You cannot bridge this gap by asking human-speed tools to work faster; security must be built for machine speed from the ground up, with discovery, ownership, and access decisions happening in real time rather than on a quarterly review cycle. Enterprises waiting for their agent programs to mature the way their human programs did are going to find out the hard way that they don’t have five years.”

Key findings:

• AI adoption has severely outpaced security controls: AI agents now represent 22% of all non-human accounts, yet 85% of organizations continue to rely on legacy identity tools not designed for agentic identities.
• Overall maturity remains anchored at foundational levels. Roughly sixty percent of organizations remain in Horizons 1 and 2, while less than 1% have achieved Horizon 5. This lag is overwhelmingly driven by non-human identity deficits: 87% rate their human IAM capabilities as capable or better, while only 43% report mature processes for agentic access.
• A pronounced awareness gap masks operational vulnerability: 80% of leaders believe the gap in their current tooling is moderate or smaller, yet the operational reality is that only 15% can provision non-human access in real time. Similarly, 57% express confidence in meeting regulatory requirements, while only 43% feel prepared to produce verifiable evidence in an AI-related audit.
• Foundations remain the primary operational roadblock. Before enterprises can realize dynamic, intent-based security, they must first master baseline hygiene and visibility. Credential lifecycle management, shadow AI discovery, and real-time monitoring are rated as severe operational hurdles across the market.
• The business value of non-human identity security is immediate and measurable: Mature identity programs deliver significant business velocity. 62% of organizations that have invested in securing non-human identities report measurable productivity gains, and 46% report safer, faster AI deployment. Looking ahead, 76% of leaders expect stronger identity governance to improve their eligibility for — or the terms of — cyber insurance.

The report concludes that the mandate for security leaders is to move from a fragmented, human-centric approach to a unified identity fabric that governs all identity types—human, machine, and AI agent—with continuous, context-aware automation. By advancing from foundational tiers (Horizons 1-2)—where organizations struggle with manual controls and lack basic visibility—to advanced maturity (Horizons 4-5), enterprises gain the real-time visibility and automated policy enforcement needed to secure autonomous agents. This transition pays off well beyond basic compliance; mature organizations are twice as likely to realize significant productivity gains and three times more successful at deploying AI safely, effectively transforming compliance from a reactive audit scramble into a state of automated, continuous assurance. This is the only path to closing the security gap while enabling the full velocity of the autonomous enterprise.

About the report
The 2026 Horizons of Identity Security report is based on a global survey of 340 senior identity, IT, cybersecurity, and risk leaders conducted by SailPoint, evaluating organizations across strategy, operating models, talent, technical confidence, and technical capabilities against a five-tier maturity model ranging from Horizon 1 (No formal program) to Horizon 5 (Ecosystem integrated).

To read the full 2026-2027 “Horizons of Identity Security” report, please visit here.
Check out the livestream of SailPoint CMO Wendy Wu revealing the findings of this year’s Horizons report from SailPoint Navigate.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world’s leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275
shannon.paulk@sailpoint.com

Expands product innovation across unified platform at Navigate 2026 delivering the industry’s first real-time defense to discover, govern and protect all human, machine and AI agent identities

Key Announcement Highlights:

• Introducing SailPoint Autonomous Agents: SailPoint debuts three classes of Autonomous Agents that enforce policy, right-size privileges, and protect systems without disrupting legitimate business automation.
• Autonomous Identity Security Posture Management (A-ISPM): New A-ISPM uses the live identity context in SailPoint Atlas to continuously uncover critical exposures across all identity types, then closes the loop with real-time remediation.
• Expanded SailPoint Agentic and Human Fabrics: SailPoint expands its Agentic Fabric to map the entire AI agent surface area—enabling shadow AI discovery, runtime authorization, and instant ‘kill switch’ controls—while simultaneously advancing its Human Fabric with next-generation certifications and segmented identity data to give organizations finer-grained access governance.
• Enhanced Atlas capabilities and Atlas Extensibility framework: New common services, SaaS plug-ins, and Workflow enhancements, including versioning, execution history, and serial loops of up to 1,000 iterations, make Atlas a more unified and extensible foundation for scaling identity security.
• Zero Standing Privilege for humans and machines: New Just-in-Time (JIT) provisioning with conditions, plus effective privilege visibility, replaces always-on access for people, service accounts, and AI agents alike.

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — Today at Navigate 2026, its annual flagship conference, SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, announced significant new capabilities across SailPoint Agentic Fabric™ (SAF) and SailPoint Human Fabric™ (SHF), the two purpose-built products of its Identity Security solution, built on SailPoint Atlas. These innovations give enterprises what they need most in the agentic era: full visibility into every hidden AI tool, continuous compliance across human and machine workflows, the replacement of permanent access keys with temporary permissions, and the transformation of identity security from a static compliance check into real-time, automated defense.

According to the latest SailPoint Horizons of Identity Security report, 79% of enterprises are already running AI agents in production, yet only 2% have deployed identity security tools purpose-built to govern and secure them. Meanwhile, enterprises are stuck between static reviews that are outdated the moment they finish and posture dashboards that flag risks but can’t fix them.

Introducing SailPoint Autonomous Agents
When AI agents invoke MCP tool calls at machine speed, human review of every action is impossible. SailPoint announced Autonomous Agents, a fleet of specialized AI agents built to govern and protect the agentic ecosystem. Unlike generic tools that simply shut agents down when anomalies occur, Autonomous Agents use identity context to tell legitimate intent from malicious activity, stopping threats while keeping productive agents running. These Autonomous Agents actively govern the agentic lifecycle: continuously monitoring runtime actions, intercepting threats, and right-sizing permissions to enforce zero standing privilege at machine speed.

Matt Mills, President of SailPoint, said:
“Autonomous agents are no longer just experimental copilots; they are becoming the primary execution layer of modern enterprises. Enterprises cannot afford to slow down AI innovation out of fear, nor can they afford ungoverned access chaos. Moving beyond Zero Trust to Autonomous Identity allows organizations to master the converged human-plus-AI workforce, eliminate invisible risk, and innovate with complete confidence.”

Chandra Gnanasambandam, EVP of Product and Chief Technology Officer, said:
“The idea that a security admin is going to review and approve access for a group of autonomous agents making 10,000 tool calls a second isn’t just outdated—it’s a fantasy. The only way to govern autonomous machines is with autonomous machine defense. We’ve built Autonomous Agents so enterprises can stop the threat, save the good agents, and bring human and non-human identity into real-time. In a near-AGI world, standing privilege is dead.”

Autonomous Identity Security Posture Management (A-ISPM) goes beyond the dashboard
Using the live identity context in SailPoint Atlas, SailPoint’s new A-ISPM continuously detects dormant accounts, partially offboarded identities, orphaned access, shadow admins, and privileged outliers hidden deep in access paths. It then closes the loop on each organization’s terms, with remediation ranging from one-click fixes, such as revoking access, disabling an identity or AI agent, or assigning an owner, to fully automated policy enforcement.

New automation and global compliance upgrades
SailPoint is advancing global identity security with powerful new updates across its platform. The company introduced new updates to the SailPoint Atlas engine with advanced automation workflows to help enterprises scale security, while also launching IdentityIQ 9.0 to make everyday access governance simpler and more secure for business users. To support this growth, SailPoint is also expanding its global footprint—opening a new data center in South Korea and preparing to meet some of the strictest federal and financial compliance standards, including FedRAMP High, PCI DSS 4.0, and EU Sovereign Cloud.

Delivering four core customer outcomes through new innovations
SailPoint delivers autonomous identity and a host of customer benefits and improved security outcomes across its Identity Security platform. New product innovations showcased at Navigate enable customers to realize these four critical business outcomes:

• Comprehensive discovery: Security teams can’t govern what they can’t see. Every agent, credential, and data store that never reach the identity program becomes access no one owns. New endpoint and browser sensors, SIEM and XDR telemetry, and vault and pipeline NHI discovery bring MCP servers, tools, credentials, and data stores into view. Data Access Security adds classification integrations with Microsoft Purview and BigID, plus new connectors for Atlassian Confluence, Google BigQuery, and AWS Redshift.
• Enabling compliance: Auditors are asking how AI agents are governed, and most organizations can’t yet produce the evidence. New Agent Audit turns agent inventory and governance activity into framework-aligned evidence reports that can be exported in one action, customized, or scheduled, making audit preparation repeatable.
• Strengthening security posture: Standing privilege is invisible risk. Every always-on account is an open door for attackers. Just-in-Time provisioning (JIT-P) grants access only when needed, with conditions such as business justification or reauthentication and activation through Slack or ServiceNow. Agentic Fabric delivers prompt monitoring with policy-based redaction and blocking and behavioral risk detection. Human Fabric features a CrowdStrike Foundry App and SecOps containment actions with a full audit trail.
• Streamlining operations: Governance has become too admin-heavy, and manual processes can’t keep pace with the volume of human and agent access. Human Fabric will now offer next-generation access requests with an embedded Harbor Pilot Access Request Agent. The upcoming Harbor Pilot Policy Agent lets administrators explain and draft access policies for people and agents in plain language, and Agentic Fabric provides one-click agent lifecycle controls and an agent kill switch.

Platform milestone: SailPoint Agentic Fabric + Entro integration
Also announced during Navigate, the Entro Security integration into SailPoint Agentic Fabric will soon be complete. The integration includes Entro-powered credential lineage, exposed secret discovery, and prompt-intent monitoring into Agentic Fabric, extending governance to secrets and credentials that AI agents and NHIs depend on.

Availability
Capabilities across SailPoint Agentic Fabric, SailPoint Human Fabric, and SailPoint Atlas are rolling out globally beginning at Navigate 2026. A-ISPM, the Harbor Pilot Policy Agent, and the Proofpoint integration are expected in Q4 FY27.

New Success Acceleration service packages combine expert-led roadmaps, vertical-specific deployment accelerators, AI-driven risk reduction, and continuous compliance support to help customers reach zero standing privilege and realize value faster.

To watch Navigate 2026 keynotes and product demonstrations live or on demand, visit www.sailpoint.com/navigate.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world’s leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to SailPoint’s expectations regarding announcements made at Navigate. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “expects,” “plans,” “anticipates,” “could,” “would,” “plan to,” “intend to,” “believe,” or “goal” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are not guarantees of future performance, but are based on management’s current expectations, assumptions and beliefs concerning future developments and their potential effect on us, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our expectations expressed or implied in these forward-looking statements may not turn out to be correct. The development, release, and timing of any features or functionality described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if available, basis, may not be delivered at all and should not be relied on in making a purchasing decision, and could be materially different from our expectations because of various risks.

Important factors, some of which are beyond our control, that could cause actual results to differ materially from our historical results or those expressed or implied by these forward-looking statements include the following: our ability to deepen our relationships with existing customers; the growth in the market for identity security solutions; our ability to maintain successful relationships with each of our partners; our ability to compete successfully against current and future competitors; the increasing complexity of our operations; our ability to maintain and enhance our brand or reputation as an industry leader and innovator; unfavorable conditions in our industry or the global economy; our ability to successfully introduce, use, and integrate artificial intelligence (AI) with our solutions; breaches in our security, cyber attacks, or other cyber risks; interruptions, outages, or other disruptions affecting the delivery of our SaaS solution or any of the third-party cloud-based systems that we use in our operations; our ability to adapt and respond to rapidly changing technology, industry standards, regulations, or customer needs, requirements, or preferences; real or perceived errors, failures, or disruptions in our platform or solutions; and the ability of our platform and solutions to effectively interoperate with our customers’ existing or future IT infrastructures.

More information on these risks and other potential factors that could affect our financial results is included in our reports and other documents filed with the Securities and Exchange Commission including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in our most recently filed Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.

The development, release, and timing of any features, functionality, capabilities, or services described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if, available basis and may not be delivered at all and must not be relied on in making a purchasing or investing decision.

Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275
shannon.paulk@sailpoint.com

Expands product innovation across unified platform at Navigate 2026 delivering the industry’s first real-time defense to discover, govern and protect all human, machine and AI agent identities

Key Announcement Highlights:

• Introducing SailPoint Autonomous Agents: SailPoint debuts three classes of Autonomous Agents that enforce policy, right-size privileges, and protect systems without disrupting legitimate business automation.
• Autonomous Identity Security Posture Management (A-ISPM): New A-ISPM uses the live identity context in SailPoint Atlas to continuously uncover critical exposures across all identity types, then closes the loop with real-time remediation.
• Expanded SailPoint Agentic and Human Fabrics: SailPoint expands its Agentic Fabric to map the entire AI agent surface area—enabling shadow AI discovery, runtime authorization, and instant ‘kill switch’ controls—while simultaneously advancing its Human Fabric with next-generation certifications and segmented identity data to give organizations finer-grained access governance.
• Enhanced Atlas capabilities and Atlas Extensibility framework: New common services, SaaS plug-ins, and Workflow enhancements, including versioning, execution history, and serial loops of up to 1,000 iterations, make Atlas a more unified and extensible foundation for scaling identity security.
• Zero Standing Privilege for humans and machines: New Just-in-Time (JIT) provisioning with conditions, plus effective privilege visibility, replaces always-on access for people, service accounts, and AI agents alike.

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — Today at Navigate 2026, its annual flagship conference, SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, announced significant new capabilities across SailPoint Agentic Fabric™ (SAF) and SailPoint Human Fabric™ (SHF), the two purpose-built products of its Identity Security solution, built on SailPoint Atlas. These innovations give enterprises what they need most in the agentic era: full visibility into every hidden AI tool, continuous compliance across human and machine workflows, the replacement of permanent access keys with temporary permissions, and the transformation of identity security from a static compliance check into real-time, automated defense.

According to the latest SailPoint Horizons of Identity Security report, 79% of enterprises are already running AI agents in production, yet only 2% have deployed identity security tools purpose-built to govern and secure them. Meanwhile, enterprises are stuck between static reviews that are outdated the moment they finish and posture dashboards that flag risks but can’t fix them.

Introducing SailPoint Autonomous Agents
When AI agents invoke MCP tool calls at machine speed, human review of every action is impossible. SailPoint announced Autonomous Agents, a fleet of specialized AI agents built to govern and protect the agentic ecosystem. Unlike generic tools that simply shut agents down when anomalies occur, Autonomous Agents use identity context to tell legitimate intent from malicious activity, stopping threats while keeping productive agents running. These Autonomous Agents actively govern the agentic lifecycle: continuously monitoring runtime actions, intercepting threats, and right-sizing permissions to enforce zero standing privilege at machine speed.

Matt Mills, President of SailPoint, said:
“Autonomous agents are no longer just experimental copilots; they are becoming the primary execution layer of modern enterprises. Enterprises cannot afford to slow down AI innovation out of fear, nor can they afford ungoverned access chaos. Moving beyond Zero Trust to Autonomous Identity allows organizations to master the converged human-plus-AI workforce, eliminate invisible risk, and innovate with complete confidence.”

Chandra Gnanasambandam, EVP of Product and Chief Technology Officer, said:
“The idea that a security admin is going to review and approve access for a group of autonomous agents making 10,000 tool calls a second isn’t just outdated—it’s a fantasy. The only way to govern autonomous machines is with autonomous machine defense. We’ve built Autonomous Agents so enterprises can stop the threat, save the good agents, and bring human and non-human identity into real-time. In a near-AGI world, standing privilege is dead.”

Autonomous Identity Security Posture Management (A-ISPM) goes beyond the dashboard
Using the live identity context in SailPoint Atlas, SailPoint’s new A-ISPM continuously detects dormant accounts, partially offboarded identities, orphaned access, shadow admins, and privileged outliers hidden deep in access paths. It then closes the loop on each organization’s terms, with remediation ranging from one-click fixes, such as revoking access, disabling an identity or AI agent, or assigning an owner, to fully automated policy enforcement.

New automation and global compliance upgrades
SailPoint is advancing global identity security with powerful new updates across its platform. The company introduced new updates to the SailPoint Atlas engine with advanced automation workflows to help enterprises scale security, while also launching IdentityIQ 9.0 to make everyday access governance simpler and more secure for business users. To support this growth, SailPoint is also expanding its global footprint—opening a new data center in South Korea and preparing to meet some of the strictest federal and financial compliance standards, including FedRAMP High, PCI DSS 4.0, and EU Sovereign Cloud.

Delivering four core customer outcomes through new innovations
SailPoint delivers autonomous identity and a host of customer benefits and improved security outcomes across its Identity Security platform. New product innovations showcased at Navigate enable customers to realize these four critical business outcomes:

• Comprehensive discovery: Security teams can’t govern what they can’t see. Every agent, credential, and data store that never reach the identity program becomes access no one owns. New endpoint and browser sensors, SIEM and XDR telemetry, and vault and pipeline NHI discovery bring MCP servers, tools, credentials, and data stores into view. Data Access Security adds classification integrations with Microsoft Purview and BigID, plus new connectors for Atlassian Confluence, Google BigQuery, and AWS Redshift.
• Enabling compliance: Auditors are asking how AI agents are governed, and most organizations can’t yet produce the evidence. New Agent Audit turns agent inventory and governance activity into framework-aligned evidence reports that can be exported in one action, customized, or scheduled, making audit preparation repeatable.
• Strengthening security posture: Standing privilege is invisible risk. Every always-on account is an open door for attackers. Just-in-Time provisioning (JIT-P) grants access only when needed, with conditions such as business justification or reauthentication and activation through Slack or ServiceNow. Agentic Fabric delivers prompt monitoring with policy-based redaction and blocking and behavioral risk detection. Human Fabric features a CrowdStrike Foundry App and SecOps containment actions with a full audit trail.
• Streamlining operations: Governance has become too admin-heavy, and manual processes can’t keep pace with the volume of human and agent access. Human Fabric will now offer next-generation access requests with an embedded Harbor Pilot Access Request Agent. The upcoming Harbor Pilot Policy Agent lets administrators explain and draft access policies for people and agents in plain language, and Agentic Fabric provides one-click agent lifecycle controls and an agent kill switch.

Platform milestone: SailPoint Agentic Fabric + Entro integration
Also announced during Navigate, the Entro Security integration into SailPoint Agentic Fabric will soon be complete. The integration includes Entro-powered credential lineage, exposed secret discovery, and prompt-intent monitoring into Agentic Fabric, extending governance to secrets and credentials that AI agents and NHIs depend on.

Availability
Capabilities across SailPoint Agentic Fabric, SailPoint Human Fabric, and SailPoint Atlas are rolling out globally beginning at Navigate 2026. A-ISPM, the Harbor Pilot Policy Agent, and the Proofpoint integration are expected in Q4 FY27.

New Success Acceleration service packages combine expert-led roadmaps, vertical-specific deployment accelerators, AI-driven risk reduction, and continuous compliance support to help customers reach zero standing privilege and realize value faster.

To watch Navigate 2026 keynotes and product demonstrations live or on demand, visit www.sailpoint.com/navigate.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world’s leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to SailPoint’s expectations regarding announcements made at Navigate. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “expects,” “plans,” “anticipates,” “could,” “would,” “plan to,” “intend to,” “believe,” or “goal” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are not guarantees of future performance, but are based on management’s current expectations, assumptions and beliefs concerning future developments and their potential effect on us, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our expectations expressed or implied in these forward-looking statements may not turn out to be correct. The development, release, and timing of any features or functionality described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if available, basis, may not be delivered at all and should not be relied on in making a purchasing decision, and could be materially different from our expectations because of various risks.

Important factors, some of which are beyond our control, that could cause actual results to differ materially from our historical results or those expressed or implied by these forward-looking statements include the following: our ability to deepen our relationships with existing customers; the growth in the market for identity security solutions; our ability to maintain successful relationships with each of our partners; our ability to compete successfully against current and future competitors; the increasing complexity of our operations; our ability to maintain and enhance our brand or reputation as an industry leader and innovator; unfavorable conditions in our industry or the global economy; our ability to successfully introduce, use, and integrate artificial intelligence (AI) with our solutions; breaches in our security, cyber attacks, or other cyber risks; interruptions, outages, or other disruptions affecting the delivery of our SaaS solution or any of the third-party cloud-based systems that we use in our operations; our ability to adapt and respond to rapidly changing technology, industry standards, regulations, or customer needs, requirements, or preferences; real or perceived errors, failures, or disruptions in our platform or solutions; and the ability of our platform and solutions to effectively interoperate with our customers’ existing or future IT infrastructures.

More information on these risks and other potential factors that could affect our financial results is included in our reports and other documents filed with the Securities and Exchange Commission including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in our most recently filed Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.

The development, release, and timing of any features, functionality, capabilities, or services described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if, available basis and may not be delivered at all and must not be relied on in making a purchasing or investing decision.

Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275
shannon.paulk@sailpoint.com

Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives

Pelthos gains enhanced commercial coverage through a regional commercial health plan representing approximately 3 million covered lives

Formulary coverage for ZELSUVMI increases to 127 million commercially covered lives

DURHAM, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos” or the “Company”), today announced that it signed an agreement with a major Pharmacy Benefit Manager (“PBM”) to open access to ZELSUVMI^® (berdazimer) topical gel, 10.3%, covering 24 million covered lives. The Company also received a formulary update enhancing access to ZELSUVMI with a regional health plan that covers approximately 3 million lives. These significant updates have expanded patient access to ZELSUVMI, an important priority for Pelthos. ZELSUVMI now has formulary coverage across 127 million or 69% of commercially covered lives and strong Medicaid coverage of more than 70 million or 100% of covered lives.

“Expanding patient access to ZELSUVMI has been a top priority for Pelthos since we launched the product last July,” said Sai Rangarao, Chief Commercial Officer at Pelthos. “We are pleased with our progress and remain focused on making this effective, convenient treatment available to patients and families affected by molluscum contagiosum.”

This formulary agreement affects one of the largest PBMs in the U.S., which manages prescription drug benefits for employers, health plans and government programs. The PBM serves roughly one in three Americans and added ZELSUVMI to its national formulary without requiring prior authorization, effective October 1, 2026. The second formulary update, which took effect in September, serves roughly 3 million members.

Pelthos launched ZELSUVMI for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older in July 2025. ZELSUVMI is a novel, topical nitric oxide-releasing gel for the treatment of molluscum. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application and can be used to treat molluscum contagiosum infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections.

About Molluscum Contagiosum
Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. This highly contagious viral skin condition afflicts an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States, most of them in children.^1,2,3 Individuals with compromised immune systems are at an elevated risk of contracting molluscum, with the condition impacting approximately 20% of HIV patients.⁴ Molluscum infections spread to others through contact with infected persons or contaminated objects like towels, toys, furniture, swimming pools, and other surfaces. Molluscum infections present with raised, flesh-colored or red bumps that can appear anywhere on the body, including the face, hands, trunk, genitals, back of the knees, armpits, and other sensitive areas. People with molluscum may suffer discomfort from itching, secondary bacterial infections from scratching, or atopic dermatitis, as well as immense social stigma from having visible molluscum lesions that may persist for months to years. It is estimated that 30% of children will have lesions that persist beyond 18 months.⁵ Up to 73% of children with molluscum go untreated.

About ZELSUVMI (berdazimer) topical gel, 10.3%
ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI received a novel drug designation from the U.S. Food and Drug Administration in 2024 and is the first and only approved topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician’s office, or other medical setting to treat this highly contagious viral skin infection. The product was developed using the proprietary nitric oxide-based technology platform, NITRICIL™, now owned by Ligand Pharmaceuticals Incorporated. Complete prescribing information and important safety information is available at www.zelsuvmi.com.

IMPORTANT SAFETY INFORMATION

Contraindications: None.

Warnings: Application site reactions, including, allergic contact dermatitis occurred. Discontinue ZELSUVMI and initiate appropriate therapy.

Adverse Reactions: The most commonly reported adverse reactions (1%) are application site reactions including pain such as burning or stinging sensations (18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%).

Forward-Looking Statements
This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) our belief that the new pharmacy benefit manager agreement will expand patient access to ZELSUVMI, (ii) our plans for continued commercial growth and increased coverage for ZELSUVMI, and (iii) the Company’s future opportunities, strategy and plans in the market. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to our reliance on third-party partners for market access and distribution; the possibility that ZELSUVMI may not achieve market acceptance or broad formulary coverage; our ability to maintain regulatory approvals; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI^® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI^® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE^® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

__________________________________
¹ ZELSUVMI. Prescribing information. LNHC, Inc. 2024.
² Browning JC, Enloe C, Cartwright M, et al. Efficacy and safety of topical nitric oxide-releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2022;158(8):871-878
³ Han H, Smythe C, Yousefian F, Berman B. Molluscum contagiosum virus evasion of immune surveillance: a review. J Drugs Dermatol. 2023;22(2):182-189.
⁴ Neal Bhatia, Adelaide A Hebert, James Q Del Rosso. Comprehensive Management of Molluscum Contagiosum: Assessment of Clinical Associations, Comorbidities, and Management Principles. Journal of Clinical and Aesthetic Dermatology. 2023 Aug;16(8 Suppl 1):S12–S17
⁵ Olsen JR, Gallacher J, Finlay A, Piguet V, Francis NA. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15:190-195

Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives

Pelthos gains enhanced commercial coverage through a regional commercial health plan representing approximately 3 million covered lives

Formulary coverage for ZELSUVMI increases to 127 million commercially covered lives

DURHAM, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos” or the “Company”), today announced that it signed an agreement with a major Pharmacy Benefit Manager (“PBM”) to open access to ZELSUVMI^® (berdazimer) topical gel, 10.3%, covering 24 million covered lives. The Company also received a formulary update enhancing access to ZELSUVMI with a regional health plan that covers approximately 3 million lives. These significant updates have expanded patient access to ZELSUVMI, an important priority for Pelthos. ZELSUVMI now has formulary coverage across 127 million or 69% of commercially covered lives and strong Medicaid coverage of more than 70 million or 100% of covered lives.

“Expanding patient access to ZELSUVMI has been a top priority for Pelthos since we launched the product last July,” said Sai Rangarao, Chief Commercial Officer at Pelthos. “We are pleased with our progress and remain focused on making this effective, convenient treatment available to patients and families affected by molluscum contagiosum.”

This formulary agreement affects one of the largest PBMs in the U.S., which manages prescription drug benefits for employers, health plans and government programs. The PBM serves roughly one in three Americans and added ZELSUVMI to its national formulary without requiring prior authorization, effective October 1, 2026. The second formulary update, which took effect in September, serves roughly 3 million members.

Pelthos launched ZELSUVMI for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older in July 2025. ZELSUVMI is a novel, topical nitric oxide-releasing gel for the treatment of molluscum. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application and can be used to treat molluscum contagiosum infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections.

About Molluscum Contagiosum
Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. This highly contagious viral skin condition afflicts an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States, most of them in children.^1,2,3 Individuals with compromised immune systems are at an elevated risk of contracting molluscum, with the condition impacting approximately 20% of HIV patients.⁴ Molluscum infections spread to others through contact with infected persons or contaminated objects like towels, toys, furniture, swimming pools, and other surfaces. Molluscum infections present with raised, flesh-colored or red bumps that can appear anywhere on the body, including the face, hands, trunk, genitals, back of the knees, armpits, and other sensitive areas. People with molluscum may suffer discomfort from itching, secondary bacterial infections from scratching, or atopic dermatitis, as well as immense social stigma from having visible molluscum lesions that may persist for months to years. It is estimated that 30% of children will have lesions that persist beyond 18 months.⁵ Up to 73% of children with molluscum go untreated.

About ZELSUVMI (berdazimer) topical gel, 10.3%
ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI received a novel drug designation from the U.S. Food and Drug Administration in 2024 and is the first and only approved topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician’s office, or other medical setting to treat this highly contagious viral skin infection. The product was developed using the proprietary nitric oxide-based technology platform, NITRICIL™, now owned by Ligand Pharmaceuticals Incorporated. Complete prescribing information and important safety information is available at www.zelsuvmi.com.

IMPORTANT SAFETY INFORMATION

Contraindications: None.

Warnings: Application site reactions, including, allergic contact dermatitis occurred. Discontinue ZELSUVMI and initiate appropriate therapy.

Adverse Reactions: The most commonly reported adverse reactions (1%) are application site reactions including pain such as burning or stinging sensations (18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%).

Forward-Looking Statements
This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) our belief that the new pharmacy benefit manager agreement will expand patient access to ZELSUVMI, (ii) our plans for continued commercial growth and increased coverage for ZELSUVMI, and (iii) the Company’s future opportunities, strategy and plans in the market. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to our reliance on third-party partners for market access and distribution; the possibility that ZELSUVMI may not achieve market acceptance or broad formulary coverage; our ability to maintain regulatory approvals; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI^® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI^® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE^® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

__________________________________
¹ ZELSUVMI. Prescribing information. LNHC, Inc. 2024.
² Browning JC, Enloe C, Cartwright M, et al. Efficacy and safety of topical nitric oxide-releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2022;158(8):871-878
³ Han H, Smythe C, Yousefian F, Berman B. Molluscum contagiosum virus evasion of immune surveillance: a review. J Drugs Dermatol. 2023;22(2):182-189.
⁴ Neal Bhatia, Adelaide A Hebert, James Q Del Rosso. Comprehensive Management of Molluscum Contagiosum: Assessment of Clinical Associations, Comorbidities, and Management Principles. Journal of Clinical and Aesthetic Dermatology. 2023 Aug;16(8 Suppl 1):S12–S17
⁵ Olsen JR, Gallacher J, Finlay A, Piguet V, Francis NA. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15:190-195

BROOKFIELD, NEWS, Oct. 06, 2026 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners will hold its third quarter 2026 conference call and webcast on Friday, November 6, 2026, at 9:00 a.m. (ET).

Results will be released that morning before 7:00 a.m. (ET) and will be available on our website at https://bip.brookfield.com.

Participants can join by conference call or webcast.

Conference Call

• Please pre-register at: BIP2026Q3ConferenceCall
• Upon registering, you will be emailed a dial-in number and unique PIN. This process will bypass the operator and avoid the queue.

Webcast

• Please join and register at: BIP2026Q3Webcast

About Brookfield Infrastructure

Brookfield Infrastructure is a leading global infrastructure company that owns and operates high-quality, long-life assets in the utilities, transport, midstream and data sectors across the Americas, Asia Pacific and Europe. We are focused on assets that have contracted and regulated revenues that generate predictable and stable cash flows. Investors can access its portfolio either through Brookfield Infrastructure Partners L.P. (NYSE: BIP; TSX: BIP.UN), a Bermuda-based limited partnership, or Brookfield Infrastructure Corporation (NYSE, TSX: BIPC), a Canadian corporation. Further information is available at https://bip.brookfield.com.

Brookfield Infrastructure is the flagship listed infrastructure company of Brookfield Asset Management, a global alternative asset manager, headquartered in New York with over $1 trillion of assets under management. For more information, go to https://brookfield.com.

Contact Information

Media John Hamlin Director, Communications Tel: +44 204 557 4334 Email: john.hamlin@brookfield.com

Investor Relations Stephen Fukuda Managing Director, Corporate Development & Investor Relations Tel: +1 (416) 956 5129 Email: stephen.fukuda@brookfield.com

BROOKFIELD, NEWS, Oct. 06, 2026 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners will hold its third quarter 2026 conference call and webcast on Friday, November 6, 2026, at 9:00 a.m. (ET).

Results will be released that morning before 7:00 a.m. (ET) and will be available on our website at https://bip.brookfield.com.

Participants can join by conference call or webcast.

Conference Call

• Please pre-register at: BIP2026Q3ConferenceCall
• Upon registering, you will be emailed a dial-in number and unique PIN. This process will bypass the operator and avoid the queue.

Webcast

• Please join and register at: BIP2026Q3Webcast

About Brookfield Infrastructure

Brookfield Infrastructure is a leading global infrastructure company that owns and operates high-quality, long-life assets in the utilities, transport, midstream and data sectors across the Americas, Asia Pacific and Europe. We are focused on assets that have contracted and regulated revenues that generate predictable and stable cash flows. Investors can access its portfolio either through Brookfield Infrastructure Partners L.P. (NYSE: BIP; TSX: BIP.UN), a Bermuda-based limited partnership, or Brookfield Infrastructure Corporation (NYSE, TSX: BIPC), a Canadian corporation. Further information is available at https://bip.brookfield.com.

Brookfield Infrastructure is the flagship listed infrastructure company of Brookfield Asset Management, a global alternative asset manager, headquartered in New York with over $1 trillion of assets under management. For more information, go to https://brookfield.com.

Contact Information

Media John Hamlin Director, Communications Tel: +44 204 557 4334 Email: john.hamlin@brookfield.com

Investor Relations Stephen Fukuda Managing Director, Corporate Development & Investor Relations Tel: +1 (416) 956 5129 Email: stephen.fukuda@brookfield.com

Transactions during 29 September 2026 – 05 October 2026
On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.

The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.

The following transactions were made under the share buy-back program 29 September – 05 October 2026:

	Number of shares bought	Average purchase price	Amount (DKK)
Accumulated, last announcement 29 September 2026 30 September 2026 01 October 2026 02 October 2026 05 October 2026	14,349,667 240,000  275,000  200,000  122,000  18,683	16.45 16.26 16.38 16.15 16.11 16.78	236,115,285 3,901,392 4,504,748 3,230,000 1,964,871 313,416
Total, 29 September – 05 October 2026	855,683	16.26	13,914,427
Accumulated under the program	15,205,350	16.44	250,029,712

With the transactions stated above Alm. Brand A/S holds a total of 47,942,022 own shares, corresponding to 3.41% of the total number of outstanding shares.

Contact
Please direct any questions regarding this announcement to:

Investors and equity analysts:                                 

VP, Head of Investor Relations & ESG                    
Mads Thinggaard                                                       
Mobile no, +45 2025 5469                                      

Attachments

• Alm Brand_Share buyback 29 September – 05 October 2026
• AS 55 2026 – Transactions under share buyback program